Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
8.86
-0.02 (-0.23%)
Feb 19, 2026, 2:22 PM EST - Market open
Elicio Therapeutics Employees
Elicio Therapeutics had 32 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
32
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,433,031
Market Cap
154.83M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 32 | 0 | - |
| Dec 31, 2023 | 32 | 9 | 39.13% |
| Dec 31, 2022 | 23 | -1 | -4.17% |
| Dec 31, 2021 | 24 | 2 | 9.09% |
| Dec 31, 2020 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fate Therapeutics | 181 |
| ProQR Therapeutics | 166 |
| Zentalis Pharmaceuticals | 166 |
| Caribou Biosciences | 147 |
| Adagene | 138 |
| Rani Therapeutics Holdings | 106 |
| Nkarta | 105 |
| Compugen | 74 |
ELTX News
- 1 day ago - Elicio Therapeutics Reports Inducement Grants - GlobeNewsWire
- 2 months ago - Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial - GlobeNewsWire
- 3 months ago - Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer - GlobeNewsWire
- 3 months ago - Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 3 months ago - Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears Imminent - Seeking Alpha
- 3 months ago - Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC - GlobeNewsWire
- 3 months ago - Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting - GlobeNewsWire
- 4 months ago - Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial - GlobeNewsWire